We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+91.23%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$735M
AUM Growth
+$18.1M
Cap. Flow
+$54.1M
Cap. Flow %
7.36%
Top 10 Hldgs %
42.08%
Holding
212
New
67
Increased
34
Reduced
65
Closed
41

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$11.6M
2
TGTX icon
TG Therapeutics
TGTX
+$8.36M
3
BPMC
Blueprint Medicines
BPMC
+$7.73M
4
FBRX icon
Forte Biosciences
FBRX
+$7.25M
5
VIR icon
Vir Biotechnology
VIR
+$7.08M

Top Sells

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$19.2M
2
ONC
BeOne Medicines Ltd
ONC
+$18M
3
SLNO
Soleno Therapeutics
SLNO
+$11.5M
4
RCUS icon
Arcus Biosciences
RCUS
+$5.97M
5
TECX
Tectonic Therapeutic
TECX
+$5.28M

Sector Composition

Rank Sector Weight
1 Healthcare 47.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QNRX
151
Quoin Pharmaceuticals
QNRX
$8.94M
$179K 0.02%
+7,857
New +$180K
AEON icon
152
AEON Biopharma
AEON
$12.9M
$139K 0.02%
3,577
-6
-0.2% -$349
MNPR icon
153
Monopar Therapeutics
MNPR
$726M
$130K 0.02%
+5,908
New +$99.1K
APLS
154
DELISTED
Apellis Pharmaceuticals
APLS
$115K 0.02%
+3,594
New +$108K
HOOK
155
DELISTED
HOOKIPA Pharma
HOOK
$107K 0.01%
52,996
-80
-0.2% -$248
TPST icon
156
Tempest Therapeutics
TPST
$13.7M
$87.9K 0.01%
8,099
-24
-0.3% -$310
AMIX
157
Autonomix Medical
AMIX
$1.87M
$75.2K 0.01%
+952
New +$168K
STOK icon
158
Stoke Therapeutics
STOK
$1.8B
$75K 0.01%
6,798
-18
-0.3% -$221
SGMT icon
159
Sagimet Biosciences
SGMT
$439M
$53.9K 0.01%
11,984
-375,581
-97% -$1.9M
CADL icon
160
CALL
Candel Therapeutics
CADL
$733M
$31.2K ﹤0.01%
+3,600
New +$21.3K
CADL icon
161
PUT
Candel Therapeutics
CADL
$733M
$31.2K ﹤0.01%
+3,600
New +$21.3K
SYBX
162
DELISTED
Synlogic
SYBX
$28K ﹤0.01%
20,422
-26
-0.1% -$37
RLMD icon
163
Relmada Therapeutics
RLMD
$557M
$20.9K ﹤0.01%
40,270
-99
-0.2% -$241
IMVT icon
164
Immunovant
IMVT
$7.93B
$14.9K ﹤0.01%
+600
New +$17K
BCLI
165
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$13.7K ﹤0.01%
+6,016
New +$11.1K
CADL icon
166
Candel Therapeutics
CADL
$733M
$12.2K ﹤0.01%
+1,400
New +$8.27K
CTMX icon
167
CytomX Therapeutics
CTMX
$675M
$9.19K ﹤0.01%
8,924
– –
EWTX icon
168
PUT
Edgewise Therapeutics
EWTX
$4.13B
$5.34K ﹤0.01%
+200
New +$6.37K
CBIO
169
Crescent Biopharma
CBIO
$535M
$1.62K ﹤0.01%
+65
New +$1.77K
FDMT icon
170
4D Molecular Therapeutics
FDMT
$532M
$223 ﹤0.01%
40
+1
+3% +$8
GALT icon
171
Galectin Therapeutics
GALT
$196M
$129 ﹤0.01%
+100
New +$240
ALNY icon
172
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-8,741
Closed -$2.4M
AMGN icon
173
Amgen
AMGN
$208B
– –
-13,300
Closed -$3.95M
APGE icon
174
CALL
Apogee Therapeutics
APGE
$10.1B
– –
-5,000
Closed -$294K
APLS
175
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-150,000
Closed -$4.33M
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Ikarian Capital held 212 positions worth $735M, up 2.5% from $717M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital deployed $54.1M of net new capital in Q4 2024, opening 67 new positions and adding to 34 existing holdings. Its largest new stake was Scholar Rock: 357,185 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 45% a quarter earlier.

On the sell side, the largest reduction was Tarsus Pharmaceuticals, an estimated $19.2M trimmed.

  • Ikarian Capital's largest Q4 2024 buy was Scholar Rock: 357,185 shares worth $15.4M.
  • Ikarian Capital added most to Blueprint Medicines in Q4 2024, an estimated $7.73M increase.
  • Ikarian Capital's biggest Q4 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $19.2M.
  • Ikarian Capital fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $18M.
  • Ikarian Capital's ten largest holdings make up 42% of its $735M portfolio in Q4 2024.
  • Ikarian Capital opened 67 new positions and closed 41 in Q4 2024.
  • Ikarian Capital's portfolio value rose 2.5% quarter-over-quarter to $735M.

Based on Ikarian Capital's 13F filing for Q4 2024, filed 14 Feb 2025.